Superhydrophobic Heart Valve Prosthesis

项目摘要： 目前所有的人工心脏瓣膜都患有并发症。机械心脏瓣膜（HV）需要终身使用 抗凝治疗，而基于固定组织的生物人工心脏瓣膜受到耐久性的困扰， 免疫原性和钙化问题。带涡流的超疏水（SH）双叶机械心脏瓣膜 发生器（VG）技术有望消除对抗凝治疗的需要。我们的实验室开发了一种 SH双叶机械心脏瓣膜（BMHV），带VG，可显著改善表面血液相容性 气体消除湍流应力，从而减少血小板活化。初步工作表明，SH表面 相对于普通热解碳瓣叶，血栓形成可能性显著降低。此外，我们已经 证明了制造BMHV并将其与VG组装成可植入BMHV的可行性。 目前的R 01研究旨在评估SH BMHV与VG作为当前心脏的潜在替代方案的有效性 阀门技术通过微调材料成分和加工工艺，以满足耐久性和抗血栓形成 心脏瓣膜的要求。我们的中心假设是：具有涡流发生器流的超疏水BMHV 控制技术将需要显著更少的抗凝治疗。这在三个目标中得到检验。要求1 重点阐明瓣叶组成和处理对血液相容性的影响，同时优化 涂层的强度和血液相容性。目的2量化SH的心脏瓣膜血流动力学性能 与VG BMHV配合使用，以确定理想的SH+VG配置，实现上级血液动力学和最小血液流量 损害目的3是了解SH与VG BMHV在试验绵羊体内的血液相容性 study.该提案由Lakshmi Prasad Dasi博士领导，他是一位训练有素的年轻研究员， 心脏瓣膜工程和心血管生物力学，以及几种心脏瓣膜技术的发明者 包括VG和新型生物分子聚合物小叶。多PI是科塔博士，他是一个既定的 超疏水材料专家; Popat博士，其专长在于生物相容性和表面 纳米工程Co-Is包括Brueur博士，Bark博士，Crestanello博士，Shinoka博士和Hor博士，他们组成了一个 在体内模型、血小板生物学、手术和成像方面拥有专业知识的经验丰富的团队。如果拟议的工作 证明SH与VG BMHV不需要抗凝，引起良好的血液动力学， 耐用，这R 01赠款可能导致突破性的技术，机械HV，需要很少或根本没有 抗凝

Project Summary: All present day prosthetic heart valves suffer from complications. Mechanical heart valves (HVs) require life-long anti-coagulation therapy, while bioprosthetic heart valves based on fixed tissue are plagued with durability, immunogenic and calcification issues. Superhydrophobic (SH) bileaflet mechanical heart valves with vortex generator (VG) technology promise to eliminate the need for anti-coagulation therapy. Our lab has developed a SH bileaflet mechanical heart valve (BMHV) with VGs that drastically improve surface hemocompatibility as well as eliminate turbulent stresses, thus reducing platelet activation. Preliminary work has shown that SH surfaces remarkably reduced thrombogenic potential relative to plain pyrolytic carbon leaflets. Further, we have already demonstrated the feasibility of manufacturing BMHVs and assembling them with VGs into an implantable BMHV. The present R01 study aims to gauge the efficacy of SH BMHV with VG as a potential alternative to current heart valve technology by fine tuning material composition and processing to meet the durability and antithrombogenic requirements for heart valves. Our central hypothesis is: superhydrophobic BMHVs with vortex generator flow control technology will require significantly less anti-coagulation therapy. This is tested in three aims. Aim 1 focuses on elucidating the effects of leaflet composition and processing on hemocompatibility while optimizing the strength and hemocompatibility of the coating. Aim 2 quantifies heart valve hemodynamic performance of SH with VG BMHVs to identify the ideal SH+VG configuration for superior hemodynamics and minimum blood damage. Aim 3 focuses on understanding the in vivo hemocompatibility of SH with VG BMHV in a pilot ovine study. This proposal is led by Dr. Lakshmi Prasad Dasi, who is a well trained young investigator with expertise in heart valve engineering and cardiovascular biomechanics, and inventor of several heart valve technologies including VGs and novel biomolecule polymer leaflets. Multi-PIs are Dr. Kota, who is an established superhydrophobic materials expert; Dr. Popat whose expertise lies in bio-compatibility and surface nano-engineering. Co-Is include Dr. Brueur, Dr. Bark, Dr. Crestanello, Dr. Shinoka, and Dr. Hor who form an experienced team with expertise in in-vivo models, platelet biology, surgery, and imaging. If the proposed work demonstrates that SH with VG BMHVs do not require anti-coagulation, elicit excellent hemodynamics, and are durable, this R01 grant may lead to breakthrough technology for mechanical HVs that require little or no anticoagulation.